Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations.

MLA

Inutsuka, Yu, et al. “Osimertinib Readministration for Central Nervous System Metastases in Non-Small Cell Lung Cancer Positive for EGFR Activating Mutations.” Respiratory Investigation, vol. 62, no. 3, May 2024, pp. 334–38. EBSCOhost, https://doi.org/10.1016/j.resinv.2024.02.001.

APA

Inutsuka, Y., Iwama, E., Shiraishi, Y., Yoneshima, Y., Shibahara, D., Tanaka, K., & Okamoto, I. (2024). Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations. Respiratory Investigation, 62(3), 334–338. https://doi.org/10.1016/j.resinv.2024.02.001

Chicago

Inutsuka, Yu, Eiji Iwama, Yoshimasa Shiraishi, Yasuto Yoneshima, Daisuke Shibahara, Kentaro Tanaka, and Isamu Okamoto. 2024. “Osimertinib Readministration for Central Nervous System Metastases in Non-Small Cell Lung Cancer Positive for EGFR Activating Mutations.” Respiratory Investigation 62 (3): 334–38. doi:10.1016/j.resinv.2024.02.001.